Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27953)	2/7/1999 1:06:00 AM
From: aknahow	Read Replies (1) \| Respond to of 32384

Who would buy LGND? 1. ELAN 2. Lilly 3. ??? From a LLY press release: "Instead, Indianapolis-based Lilly said it will look to its own laboratories and pacts with biotechnology companies for new drugs needed to offset the loss of patent protection on Prozac. Cheaper generic versions of Prozac, which had $2.8 billion in 1998 sales, will hit the market sometime after 2001." Admit this is far from being a statement of intent to buy up a biotech, since it only talks of pacts but IMO they would have an interest in a take over. At first I totally disregarded the rumor and still think Tokyo Joe got his info on approvals here and that the merger rumor was a distortion of LGNDs' own acquisition, but with AGPH spoken for LGND and CORR have possibly moved up a notch as targets. Disclosure: I currently own stock in each of these.